It is with a heavy heart that we announce the passing of Robert Jennejahn, a valued contributor to Vein Therapy News. His association with our book spanned several issues, during which he made significant contributions. On the 7th of October this year, Robert passed on at the age of 71.
We would like to hear from you! Please call Gary Pittman Jr at 512-637-0373 or email firstname.lastname@example.org.
The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced observational data from 8 years of clinical practice showing that the company’s oral Factor Xa inhibitor Xarelto (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a
Stryker announced FDA 510(k) clearance of the Target Tetra detachable coil, the latest addition to the company’s Target platform. The Target Tetra device, which is specifically designed to treat small aneurysms, combines a new tetrahedral shape and softness level. According to the company, the delicate nature of small aneurysms makes